BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-882@pharmaconomics
DTSTAMP:20260707T041327Z
DTSTART;VALUE=DATE:20260630
DTEND;VALUE=DATE:20260701
SUMMARY:CPRX Phase 2 — AGAMREE (vamorolone)
DESCRIPTION:Phase 2 trial results for AGAMREE (vamorolone) in its lead indication are due Jun 30\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1369568/000119312526290768/d158010d8k.htm\n\nTrack it: https://pharmaconomics.com/e/882
URL:https://pharmaconomics.com/e/882
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:CPRX catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR